BioDlink International Company Limited announced the following change of directors (the "Directors") and chief executive of the Company with effect from 29 April 2026: Mr. Shan FU has resigned as an executive Director, the chairperson of the Board and a member and the chairperson of the Nomination Committee and the Strategy and ESG Committee of the Company; Dr. Weidong LIU has resigned as a non-executive Director, a member of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee of the Company; Ms. Hui SUN has resigned as an independent non-executive Director and a member and chairperson of the Audit and Connected Transactions Review Committee and a member of the Nomination Committee of the Company; Mr. Qing ZHANG has resigned as an independent non-executive Director and a member of the Audit and Connected Transactions Review Committee and a member and the chairperson of the Remuneration Committee of the Company; and Dr. Xuelin GU has resigned as an independent non-executive Director and a member of the Remuneration Committee, the Nomination Committee and the Strategy and ESG Committee of the Company. The Board is also announced that with effect from 29 April 2026: Dr. Jincai LI ("Dr. Li") has been appointed as an executive Director, the chairperson of the Board and the chairperson of each of the Nomination Committee and the Strategy and ESG Committee and member of the Remuneration Committee; Mr. Xiaojie XI ("Mr. Xi") has been appointed as a non-executive Director and member of each of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee of the Company; Mr. Xin FAN ("Mr. Fan") has been appointed as an independent non-executive Director and the chairperson of the Audit and Connected Transactions Review Committee and member of the Remuneration Committee of the Company; Dr. Ulf GRAWUNDER ("Dr. Grawunder") has been appointed as an independent non-executive Director and the chairperson of the Remuneration Committee and member of each of the Nomination Committee and the Strategy and ESG Committee of the Company; and Dr. Chaohong Hu ("Dr. Hu") has been appointed as an independent non-executive Director and a member of each of the Audit and Connected Transactions Review Committee and the Nomination Committee of the Company. Dr. Jincai LI Dr. Li, aged 53, is an executive Director and chairman of the Board.

He is primarily responsible for formulating overall strategic plans, business development and daily operations of the Group. Dr. Li has over 20 years of experience in biologics process development, scale-up and cGMP manufacturing (current good manufacturing practice). He has been a director of WuXi XDC since its incorporation in December 2020, and has been re-designated as an executive director and appointed as the chief executive officer of WuXi XDC since June 2023.

Under his leadership, WuXi XDC became a leading antibody drug conjugate ("ADC") and bioconjugates contract research, development and manufacturing organization ("CRDMO"), which was recognised by the 2022 World ADC Awards' Runner Up prize in the "Best CMO Provider" category and the winner of the 2023 World ADC Awards' prize in the "Best Contract Development Manufacturing Organization (CDMO)" category. Dr. Li joined WuXi Biologics (Cayman) Inc. (together with its subsidiaries, "WXB Group") in September 2011 and has served as the senior vice president at the WXB Group since May 2020. Before Dr. Li joined the WXB Group, from August 2007 to September 2011, Dr. Li had served as a group leader at Genentech Inc. where he was responsible for cell culture process development.

From April 2006 to July 2007, Dr. Li was a scientist at Tanox Inc., and from August 2001 to March 2006, Dr. Li was a staff scientist at Diversa Corporation (now BASF) where he was in charge of process development for multiple biologics projects. Dr. Li obtained a bachelor's degree in chemical engineering and technology and minor in chemistry from Tsinghua University in the People's Republic of China (the "PRC") in July 1996. Dr. Li then obtained a doctoral degree majoring in chemical and biochemical engineering from University of Maryland Baltimore County in the United States in August 2001.

Mr. Xiaojie XI Mr. Xi, aged 50, is a non-executive Director. Mr. Xi is primarily responsible for overseeing the overall financial management, financial matters and strategic development of the Group. Mr. Xi has been an executive director of WuXi XDC since June 2023 and the chief financial officer and company secretary of WuXi XDC since May 2023 and November 2023, respectively.

He brings over 20 years of financial industry experience in the United States and the PRC, including investment banking and private equity investment with many public and private companies. Prior to joining WuXi XDC, from November 2018 to May 2023, Mr. Xi had served as the chief financial officer and simultaneously from April 2020 to May 2023, a joint company secretary of Akeso Inc. Before that, from August 2017 to October 2018, he was a director at SIN Capital (HK) Limited, focusing on investments in the healthcare industry in China, and from April 2015 to July 2017, he served as a director of corporate finance and capital markets at CLSA Limited. Between October 2013 to April 2015, Mr. Xi was the vice president of investment banking and strategic advisory department at Credit Suisse AG (Hong Kong branch).

From March 2010 to April 2013, Mr. Xi served as the vice president of investment banking division at Morgan Stanley Asia Limited. During his time with the aforementioned investment banks, Mr. Xi had executed high profile transactions, including IPOs, debt and equity financings and M&As for leading companies in China.